## Mounjaro (tirzepatide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME	:	MEMBER'S FIRST NAME:			
	view (e.g., chart notes or	lab data, to support th	r. Attach any additional documentation authorization request). Information		
			☐ URGEN		
MEMBER INFORMATIO	N				
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE:	STATE: ZIP CODE:		
PATIENT INSURANCE	D NUMBER:				
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	_ WEIGHT (LB/KG):	ALLERGIES:		
IF YOU ARE NOT THE PATIENT'S AUTHORIZE	ZATION FORM WITH TH METHERAPEUTICS.COM	IIS REQUEST WHICH M/NOPP	I CAN BE FOUND AT THE		
<b>AUTHORIZED REPRESE</b>					
PRESCRIBER INFORM	ATION				
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIAL	.TY:	EMAIL ADDRES	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:		
STREET ADDRESS:					
CITY:		STATE:	STATE: ZIP CODE:		
REQUESTER (if different than prescriber):		OFFICE CONTA	OFFICE CONTACT PERSON:		
		1			
MEDICATION OR MEDI	CAL DISPENSING INFO	RMATION			
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFI	QUANTITY:		
☐ NEW THERAPY	RENEWAL IF	RENEWAL: DATE T	=		
DURATION OF THERAF	Y (SPECIFIC DATES):				
Continued on next page					

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date:11.15.25 CAT009



## Mounjaro (tirzepatide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:					
	OTHER MEDICATIONS FOR THIS	CONDITION?			
YES (if yes, complete below)					
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
☐ Type II Diabetes					
	ICD-10 Code(s):				
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.					
	in combination with a clinical trial?	Yes No			
is patient going to be using drug	in combination with a clinical trial:	□ res □ NO			
Does patient have a HbA1c greater than or equal to 7% in the last 6 months or prior to starting therapy?□ Yes □ No <i>Please submit documentation.</i>					
Is the patient currently on metformin? □ Yes □ No <i>Please submit documentation</i> .					
Has the patient failed treatment with, or had an intolerance to, metformin? $\Box$ Yes $\Box$ No <i>Please submit documentation.</i>					
Does the patient have an estimated GFR is less than-30 ml/min/1.73m <sup>2</sup> ? $\square$ Yes $\square$ No <i>Please submit documentation.</i>					
Does the patient have advanced liver disease with cirrhosis, portal hypertension, ascites, and/or hepatic encephalopathy? $\square$ Yes $\square$ No <i>Please submit documentation.</i>					
Has the patient tried generic liraglutide? □ Yes □ No Please submit documentation.					
Has the patient tried generic liraglutide for at least 6 months AND not come to HbA1c level of less than 8%?□ Yes □ No <i>Please submit documentation.</i>					
Has the patient tried a GLP-1 or a combination of GLP-1's such as Ozempic (semaglutide), Victoza (liraglutide), Rybelsus (semaglutide), Byetta (exenatide), Bydureon (exenatide), Bydureon BCise, OR Trulicity (dulaglutide) for a total GLP-1 use of at least 6 months AND not come to HbA1c level of less than 8%? ☐ Yes ☐ No Please submit documentation.					
Does the patient have a BMI greater than or equal to 23 kg/m $^2$ ? $\Box$ Yes $\Box$ No <i>Please submit documentation.</i>					
Does the patient have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome Type 2? $\Box$ Yes $\Box$ No					



## Mounjaro (tirzepatide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S I	FIRST NAME:		
Is the patient going to take Mounjaro (t (semaglutide), Victoza (liraglutide), Ryk (exenatide), Bydureon BCise or Trulicit	pelsus (semaglutide),	Byetta (exenatide), Bydureon		
Will the patient use Mounjaro (tirzepatide) in combination with a DPP-4 such as Januvia, Janumet, Janumet XR, Tradjenta, Jentadueto (XR), Onglyza, Kombiglyze XR, Nesina, Kazano, Oseni, Glyxambi, Seglujan, Qtern? □ Yes □ No				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
Please note: Not all drugs/diagnosis are or required information is received.	covered on all plans. Th	nis request may be denied unless all		
ATTESTATION: I attest the information punderstand that the Health Plan, insurer, I request the medical information necessary	Medical Group or its de	signees may perform a routine audit and		
Prescriber Signature or Electronic I.D.	Verification:	Date:		
information that is legally privileged. If you disclosure, copying, distribution, or action prohibited. If you have received this inform FAX) and arrange for the return or destruction.	are not the intended re taken in reliance on the nation in error, please n	ecipient, you are hereby notified that any e contents of these documents is strictly notify the sender immediately (via return		

**FAX THIS FORM TO:** 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201

P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

